lunes, 16 de noviembre de 2026
BuscarExplore
Inteligencia rastreable hasta la fuente

Noticias en las que puede confiar

Cada dato rastreado hasta su fuente, y verificado. Explore las empresas, los datos y las conclusiones detrás de las noticias.

Lo que estamos viendo

Conclusiones que nuestra IA extrae de los datos rastreados: léalas como interpretación, cada una respaldada por los datos y las entidades que menciona.

cycle· bullish

Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge

Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.

ECLIPSE 1ECLIPSE 2ECLIPSE 3Phase 2 SOLSTICE trial
transformation· mixed

Q4 2026 Boardroom Reckoning: Activism, Unsolicited Bids and Leadership Succession

Boards are working through a dense stretch of governance events: Helen of Troy rejecting Empower Brands' $37 cash proposal, Oasis's nominee standing at Vail Resorts' Dec 14 meeting, and a BAM take-private proposal for BEEP under special committee review. Planned CEO successions (Davis succeeding Hogan at Align), board refreshes (Mineralys, Fractyl, Bausch + Lomb), SPAC extensions (Globa Terra) and wind-downs (Elme Communities) add to the picture. Universal proxy card rules have pushed activist campaigns toward negotiated settlements. AI is a smaller thread: employers are warned that staff running confidential data through consumer AI tools may breach trade-secret agreements, which is prompting rewrites of confidentiality and invention-assignment contracts.

Helen of Troy Board of DirectorsVail Resorts 2026 Annual Meeting of StockholdersM. Ashton HudsonUniversal proxy card rules
transformation· mixed

Q3 2026 CFO Playbook: Cost Discipline, Liquidity Preservation and Portfolio Reshaping Ahead of 2027

CFOs across biotech, medtech, energy, mining, semiconductors and fintech/adtech are using Q3 2026 earnings to stress cash preservation, cost cuts and integration wrap-up. Examples include Fractyl's ~50% cut in cash burn, TriSalus's lower-burn growth plan, Infineon's falling idle costs, and NGS's final integration quarter. Capital moves are also under way: Atrium's $50M placement, a credit-facility redraw to repay convertibles, Eagle Ford and Lubes divestitures/spinoffs, and System1's planned NYSE delisting. Regulatory events (Durbin Amendment impact on Origin Bancorp, the FDA PDUFA date for ivonescimab, the Florida City Gas rate case, Alberta auto reform) set the 2027 backdrop. Little of this material concerns AI or fintech directly; the link is the Startpage monetization pressure at System1 and the Durbin effect on bank interchange.

Lara WeberTridivesh KidambiBrendan WinslowIan Eckert
transformation· mixed

Biotech Clinical Progress Meets AI-Driven Discovery Amid a Risk-Off Tech and Funding Shock

Biotech fundamentals are advancing on several fronts: Vor Biopharma's TELIGAN Phase 3 win, Incyte's PDAC data, Scribe's in vivo CRISPR program with $174.2M cash, and AI-designed viruses treating a first patient at Radical Numerics. Meanwhile, a $1 trillion tech selloff, OpenAI cutting its funding target and $3.6B in Binance withdrawals show a risk-off turn in AI and crypto capital markets. Biotech is therefore pairing real clinical and AI-enabled progress with a tighter funding backdrop, so the winners are likely to be companies with cash runways and late-stage data. Eli Lilly's strong demand and BioArctic's royalty growth show where revenue is already flowing.

Scribe Therapeutics Inc.Vor Biopharma Inc.Incyte CorporationRadical Numerics
cycle· mixed

Big Tech Selloff and Hot Inflation Meet Resilient Financial-Sector Q3 Earnings

In early November 2026 the Nasdaq had its worst day since April 2025 and the Magnificent Seven lost over $1 trillion. Pressure came from a hotter-than-expected October CPI and Democratic plans to rein in Big Tech. Meanwhile, financial services firms (East West, FNF, Aventus, LY Corp, Canara HSBC Life) reported solid Q3 results with raised guidance, fee growth and deal activity, such as the Aventus-Nomura joint venture. J.P. Morgan's selective aerospace and defense calls and a run of CEO successions suggest investors are rotating from richly valued AI and tech names toward earnings-backed value and leadership continuity.

Aventus Capital Inc.Fidelity National Financial, Inc.J.P. Morgan Chase Bank, N.A.Dominic Ng
crisis· mixed

AI-Chip Selloff Hits Semiconductors as Fundamentals Stay Strong

On Nov 5, 2026 the AI and data-center trade sold off hard. The PHLX Semiconductor Index had its worst session since March 2020, the S&P 500 had its worst day since the April 2025 tariff crash, and the Nasdaq entered correction. Nvidia leadership turmoil (reported CEO ouster plans and a spy scandal stalling export-curb tightening) and strategists downgrading US stocks and global tech to neutral added to the pressure. Company-level data stayed solid: Siltronic hit record 300mm shipments and narrowed 2026 guidance upward, and Lynx kept Micron and Sandisk at clear buy with 33% and 49% upside. Infineon's decision to stop disclosing backlog and a wave of consolidation (Winbond buying Infineon's NOR Flash and F-RAM business for USD 1.12B, Kalray/Bull) point to a cautious, restructuring phase. The Nov 6 and Nov 9 rebounds were only partial.

PHLX Semiconductor IndexNvidia spy scandalAI and data-center tradeBlue-Chip Stocks
Señales que seguimos
  • Satellite-Terrestrial Network Integration Acceleration

    Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases

  • EPKINLY Regulatory-Clinical Success Cascade

    High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

  • Smart Home AI Platform Convergence

    Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products

  • AI Integration Acceleration

    Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances

Hipótesis en estudio
  • NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools

    88% confidence · sin probar
  • Data center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers

    88% confidence · sin probar
  • LLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations

    85% confidence · sin probar
  • AI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance

    85% confidence · sin probar
  • Hyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026

    85% confidence · sin probar
Sources we've traced
all →
Source document

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

“BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, mRNA cance…”

Source document

Philadelphia Fed's Anna Paulson sees long-run federal funds rate at about 3.1%

“Philadelphia Fed's Anna Paulson sees long-run federal funds rate at about 3.1% [Philadelphia] Hardikkumar Joshi Philadelphia Federal Reserve Bank President Anna Paulson sees the long-run federal funds rate closer to the SEP median of 3.1%…”

Source document

LG Innotek Accelerates Physical AI Market Entry Through Partnership with Applied Intuition

“LG Innotek Accelerates Physical AI Market Entry Through Partnership with Applied Intuition -Signed a partnership agreement with autonomous driving software firm Applied Intuition.- Expanding collaboration beyond autonomous driving into drones and robotics to secure leadership in physical AI Maximizing module performanc…”

Source document

The Download: Pokémon Go to train world models, and the US-China race to find aliens

“MIT Technology Review - Ai Research Title: The Download: Pokémon Go to train world models, and the US-China race to find aliens Date: 2026-03-11 12:38 Source: https://www.technologyreview.com/2026/03/11/1134174/the-download-pokemon-go-train-world-models-us-china-race-find-aliens/ <p><em>This is today’s edition of </em>…”

Source document

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

“AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results NORTH CHICAGO, Ill., June 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-dur…”

Source document

Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

“Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights Scribe Therapeutics Inc…”

Every fact is traceable to the document it came from: see how we source every claim.

Latest News

View All →
Mercados que no cierran, agentes que compran: lo que está verificado y lo que aún no sabemos sobre la automatización de las finanzas
Analysis

Mercados que no cierran, agentes que compran: lo que está verificado y lo que aún no sabemos sobre la automatización de las finanzas

Nasdaq prevé una jornada de 23 horas, Cboe y Robinhood preparan contratos sobre indicadores de empresas y una startup recauda 35 millones de dólares para identificar agentes de IA. Separamos lo comprobado en documentos y en declaraciones de la SEC de lo que el material no permite afirmar, incluido el impacto en Latinoamérica.

Chips que no llegan a producirse al ritmo de la demanda, industriales que recortan para sostener beneficios: lo que dicen los directores financieros del tercer trimestre de 2026
Analysis

Chips que no llegan a producirse al ritmo de la demanda, industriales que recortan para sostener beneficios: lo que dicen los directores financieros del tercer trimestre de 2026

Lam Research dice que su previsión de ingresos sería mayor sin cuellos de botella de suministro. Dow y Union Pacific protegen márgenes con recortes y control del balance frente a la energía cara. Todas las cifras proceden de llamadas con analistas del 22 de octubre y de datos de la SEC verificados.

LM Salvado•
Temporada de resultados del tercer trimestre de 2026: del recorte de costes a la banca mexicana, cómo gestionan el dinero los directores financieros
Analysis

Temporada de resultados del tercer trimestre de 2026: del recorte de costes a la banca mexicana, cómo gestionan el dinero los directores financieros

Dow, Union Pacific y el banco mexicano Regional ofrecen tres respuestas distintas a costes de energía altos y demanda desigual. Las cifras de Dow proceden de documentos oficiales ante la SEC y verificados. Las citas de las llamadas con analistas proceden de fuentes con una fiabilidad medida de entre el 52% y el 60%, y lo indicamos.

Fintech apuesta por contratos de resultados para el minorista y por identidad para agentes de IA: lo que dicen los datos verificados
Analysis

Fintech apuesta por contratos de resultados para el minorista y por identidad para agentes de IA: lo que dicen los datos verificados

Robinhood y Cboe preparan contratos binarios sobre resultados de empresas sin comisiones hasta fin de 2026, y Baselayer capta 35 millones de dólares para verificar agentes de IA. Contrastamos ambos movimientos con las cuentas de Robinhood auditadas ante la SEC. Los datos no incluyen nada específico de España ni de Latinoamérica.

Oncología de nueva generación: biespecíficos, vacunas de ARNm e IA atraen capital, pero Summit muestra el coste de llegar al mercado
Analysis

Oncología de nueva generación: biespecíficos, vacunas de ARNm e IA atraen capital, pero Summit muestra el coste de llegar al mercado

Summit Therapeutics, que espera decisión de la FDA sobre ivonescimab el 14 de noviembre, perdió 1.080 millones de dólares en 2025 sin ingresos, según sus informes a la SEC. La Agencia Europea de Medicamentos, que rige para España, recomendó Trodelvy más Keytruda. Las promesas de la IA son, por ahora, previsiones.

Oncología ante su ventana de resultados del cuarto trimestre: la fecha del 14 de noviembre para ivonescimab y lo que dicen las cuentas de Summit
Analysis

Oncología ante su ventana de resultados del cuarto trimestre: la fecha del 14 de noviembre para ivonescimab y lo que dicen las cuentas de Summit

La FDA fijó el 14 de noviembre de 2026 como fecha límite de decisión para ivonescimab. Las cuentas de Summit, verificadas contra sus informes a la SEC, muestran cuánto cuesta llegar hasta ahí: una pérdida de 1.080 millones de dólares en 2025 y ningún ingreso. El expediente no incluye empresas españolas ni latinoamericanas.

Hecho también para máquinas

Cada dato aquí es estructurado y rastreado hasta su fuente, para que los sistemas de IA hereden la verdad de base, no afirmaciones reformuladas. Los mismos datos que una persona lee, un modelo puede consultarlos.

Obtenga vía API →